Hidradenitis Suppurativa and Smoking, Obesity, Psoriasis, Inflammatory Bowel Disease, and Systemic Sclerosis
JAMA Dermatology · 2026
DOI: 10.1001/jamadermatol.2025.5010 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, 2026. Verfasst von Rune Kjærsgaard Andersen und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospitals, Gentofte, Denmark. Hauptthemen laut MEDLINE: Psoriasis, Inflammatory Bowel Diseases, Smoking, Hidradenitis Suppurativa. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Smoking and obesity are associated with risk of hidradenitis suppurativa, and both are considered important environmental risk factors. However, a causal relationship remains unproven.
Objective
To primarily investigate the relationship between body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) and smoking and HS, and secondarily to investigate potential relationships between 3 inflammatory diseases (psoriasis, inflammatory bowel disease [IBD], and systemic sclerosis [SSc]) and HS. Design, Setting, and Participants A mendelian randomization (MR) study conducted in 2024 on 5 exposure phenotypes (BMI, smoking, psoriasis, IBD, and SSc) on the outcome of phenotype HS was conducted. The MR analyses used large genetic White European cohorts from genome-wide association studies (GWAS) of each of the 6 phenotypes. Initial analyses were conducted May, 2024, and were updated in May, 2025. Exposure The 5 exposure phenotypes using predetermined genome-wide significant single-nucleotide variants as proxies for each particular exposure.
Results
The GWAS on HS included 4814 case patients and more than 1.2 million controls from Denmark, Iceland, Finland, the UK, and the US. The BMI GWAS involved 700 000 individuals from the UK Biobank and GIANT consortium. Smoking data were obtained from 1.23 million participants in an international consortium. The psoriasis GWAS analyzed 39 498 case patients and 286 769 controls from White European populations and a DNA genetic testing company. The IBD GWAS meta-analysis included 38 155 case patients and 48 485 controls from the International Inflammatory Bowel Disease (IBD) Genetics Consortium. The SSc GWAS included 9095 case patients and 17 584 controls from White European populations. Genetic correlations ( r g ) were found between HS and all exposure phenotypes except SSc (BMI: r g = 0.36, P < .001; smoking: r g = 0.33, P < .001; IBD: r g = 0.25, P < .001; psoriasis: r g = 0.34, P < .001; SSc: r g = 0.33, P = .22). MR analyses supported an effect of BMI on HS (β = 0.87; odds ratio [OR] per BMI unit, 1.20; 95% CI, 1.17-1.23; P < .001) without signs of pleiotropy (slope: β = 0.91, P < .001, P for intercept = .76). Smoking showed a significant causal estimate (β = 0.59, P < .001), but results became inconclusive in subsequent sensitivity analyses. Among IBD, psoriasis, and SSc, results supported a causal effect of IBD on HS (β = 0.18, OR = 1.20; 95% CI, 1.15-1.24; P < .001), without signs of pleiotropy. Conclusions and Relevance These findings indicate causal effects of IBD and increased BMI on the risk of HS. This information may help physicians inform patients about disease risk contributed by modifiable lifestyle behaviors, which can be beneficial for planning lifestyle interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospitals, Gentofte, Denmark.
- Department of Immunology and Microbiology, Leo Foundation Skin Immunology Research Center, University of Copenhagen, Denmark.
- Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
- Deptartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
- Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
- Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark.
Zitieren
APA
Kjærsgaard Andersen, R., Riis, P. T., Zachariae, C., Thomsen, S. F., Quin, L., Dinh, K. M., Banasik, K., Brunak, S., Hansen, T., Hjalgrim, H., Sørensen, E., Mikkelsen, C., Ullum, H., Nyegaard, M., Bruun, M. T., Erikstrup, C., Ostrowski, S. R., Eidsmo, L., Lindhardt Saunte, D. M., …, & Jemec, G. B. E. (2026). Hidradenitis Suppurativa and Smoking, Obesity, Psoriasis, Inflammatory Bowel Disease, and Systemic Sclerosis. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2025.5010
Vancouver
Kjærsgaard Andersen R, Riis PT, Zachariae C, Thomsen SF, Quin L, Dinh KM, et al. Hidradenitis Suppurativa and Smoking, Obesity, Psoriasis, Inflammatory Bowel Disease, and Systemic Sclerosis. JAMA Dermatology. 2026. doi:10.1001/jamadermatol.2025.5010
BibTeX
@article{KjrsgaardAndersen2026,
author = {Kjærsgaard Andersen, Rune and Riis, Peter Theut and Zachariae, Claus and Thomsen, Simon Francis and Quin, Liam and Dinh, Khoa Manh and Banasik, Karina and Brunak, Søren and Hansen, Thomas and Hjalgrim, Henrik and Sørensen, Erik and Mikkelsen, Christina and Ullum, Henrik and Nyegaard, Mette and Bruun, Mie Topholm and Erikstrup, Christian and Ostrowski, Sisse Rye and Eidsmo, Liv and Lindhardt Saunte, Ditte Marie and Pedersen, Ole Birger Vesterager and Jemec, Gregor Borut Ernst},
title = {Hidradenitis Suppurativa and Smoking, Obesity, Psoriasis, Inflammatory Bowel Disease, and Systemic Sclerosis},
journal = {JAMA Dermatology},
year = {2026},
doi = {10.1001/jamadermatol.2025.5010}
}
EUVIMED